BioCentury
ARTICLE | Finance

A clinical quarter

3Q17 offers a full slate of clinical milestones and PDUFA decisions

July 8, 2017 12:20 AM UTC

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia.

The third quarter is also slated to deliver at least two dozen PDUFA and BsUFA dates, which could give at least two platform companies their first FDA approvals. ...